statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien PR Newswire TEL-AVIV...

RedHill Biopharma Ends Aemcolo Licensing Deal

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has mutually agreed with Cosmo Technologies Ltd. to terminate their exclusi...

RedHill Biopharma Terminates License Agreement for Aemcolo

RedHill Biopharma Terminates License Agreement for Aemcolo RedHill Biopharma Terminates License Agreement for Aemcolo PR Newswire TEL-AVIV, Israel and RALEIGH, NC, July 9, 2024 TEL-AVIV, Israel and...

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 RedHill Announces a New Patent Covering Opaganib in Combination with Immune...

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 PR Newswire TEL-AVIV, Israel...

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire TEL AVIV, Israel and RALEIGH...

RedHill Biopharma Secures $1.25M in Direct Offering

RedHill Biopharma Ltd (RDHL) has released an update. RedHill Biopharma Ltd. has successfully closed a registered direct offering, raising $1.25 mil...

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR...

RedHill Announces New USPTO Patent Covering Talicia Through 2034

RedHill Announces New USPTO Patent Covering Talicia Through 2034 RedHill Announces New USPTO Patent Covering Talicia Through 2034 PR Newswire TEL AVIV, Israel and RALEIGH, N.C., March 11, 2024 U.S...

RedHill Biopharma's opaganib to be evaluated by BARDA, NIH

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Volume	706,640.00
52-Wk High	$3.28
52-Wk Low	$0.257

RDHL RedHill Biopharma Ltd.

About

Feed

News

Sentiment

Fundamentals